MARK TO MARKET
·
SUBSCRIBERS

Catalist-listed SIAMH may have gone public before it was ready – MAS review group should figure out why

Can the enablers of public listings be incentivised to ensure that companies do not come to market without a credible growth story?

Ben Paul
Published Mon, Dec 16, 2024 · 05:00 AM
    • SIAMH said on Dec 12 that its proton beam therapy business has not taken off as quickly as expected.
    • SIAMH said on Dec 12 that its proton beam therapy business has not taken off as quickly as expected. PHOTO: BT FILE

    DeeperDive is a beta AI feature. Refer to full articles for the facts.

    WHEN news broke earlier this month that the external auditors of the Singapore Institute of Advanced Medicine Holdings (SIAMH) had issued a disclaimer of opinion on its latest financial statements, I imagined that the company’s share price would immediately plummet.

    Then, I looked at my trading screen and realised the stock could not plummet because it was already on the floor – and had been for some time.

    SIAMH listed on Catalist on Feb 16, following an initial public offering (IPO) at S$0.23 per share. It ended its first trading day at S$0.19. Less than a fortnight later, its shares had crashed below S$0.10.

    Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

    Copyright SPH Media. All rights reserved.